
Artiria Medical and Reverso Therapeutics awarded at BioInnovation Day 2025
4 April 2025

The 10th edition of BioInnovation Day gathered more than 250 life sciences stakeholders at Campus Biotech in Geneva. Two standout projects, Artiria Medical and Reverso Therapeutics, were honoured for their innovative contributions to stroke treatment and cardiovascular medicine.
Over 250 members of the Western Switzerland’s Health Valley convened at Campus Biotech in Geneva on 1 April 2025 for the 10th edition of BioInnovation Day (BIND), a key platform showcasing academic and entrepreneurial innovation in the region’s life sciences sector.
Organized by Unitec, PACTT, BioAlps, and the State of Geneva, with support from multiple academic institutions and innovation partners, this year’s event featured pitches from 29 promising projects spanning biotech, medtech, pharma, biotools and digital health.
Artiria Medical and Reverso Therapeutics were recognized with the Best Startup and Best Academic Project Awards, respectively. Each received a CHF 5,000 prize to support the advancement of their research and development efforts.
Reimagining stroke intervention
Winner of the Best Startup Award, Artiria Medical (EPFL Innovation Park, Wyss Center) is developing a robotic neurovascular access system to assist surgeons in performing stroke interventions. The system, described as a self-driving car for the brain, aims to reduce the complexity and duration of life-saving procedures. Featuring an articulated, atraumatic tip and wireless control, the technology offers real-time reshaping capabilities, helping to improve accessibility and training in stroke care. The award was presented by Guillaume Petit-Pierre and sponsored by Lenz & Staehelin.
Innovating anticoagulation therapies
Reverso Therapeutics, based at the University of Geneva, received the Best Academic Project Award for its development of a reversible anticoagulant inspired by blood-sucking insects. Designed for safe self-administration and rapid reversal in case of bleeding, the injectable therapy could offer a new standard of care for patients with cardiovascular conditions. The project has shown promising results in preclinical studies and was presented by Millicent Dockerill. The award was supported by Unitec and PACTT.
The event underscored Western Switzerland’s role as a hub for cutting-edge health innovation, with strong collaboration between academia, start-ups, and institutional partners.